SCHEMBL2189077

SCHEMBL2189077

CC(C)([C@@H]1CC(=O)N(c2cnc(C(F)(F)F)nc2)C1)S(=O)(=O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.41
CACNA1B Q00975 2/20 0.41
NR1I2 O75469 1/20 0.41
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP2C19 P33261 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
AKR1C3 P42330 1/20 0.38
HSD11B1 P28845 1/20 0.38
KDM4E B2RXH2 1/20 0.38
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
GRM5 P41594 1/20 0.37
PSEN1 P49768 5/20 0.37
PSEN2 P49810 5/20 0.37
APH1B Q8WW43 5/20 0.37
NCSTN Q92542 5/20 0.37
APH1A Q96BI3 5/20 0.37
PSENEN Q9NZ42 5/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12415667 1.00 CYP3A4 (0.41) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL2187721 1.00 CYP3A4 (0.41) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL2188233 0.90 CYP3A4 (0.46) CYP3A4CACNA1BNR1I2LMNACYP2C19
SCHEMBL2189802 0.89 DPP4 (0.45) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL2191232 0.89 DPP4 (0.45) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL12415654 0.89 DPP4 (0.45) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL2189687 0.86 CYP3A4 (0.44) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL2188962 0.86 CYP3A4 (0.44) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL12415646 0.86 CYP3A4 (0.44) CYP3A4CACNA1BNR1I2LMNASMN1; SMN2
SCHEMBL2192701 0.84 HCRTR1 (0.43) CYP3A4CACNA1BNR1I2SMN1; SMN2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CYP3A4 939/4885CACNA1B 23/4885NR1I2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.